These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 16109780)

  • 1. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
    Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG
    Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.
    Warkentin TE; Sheppard JI; Sun JC; Jung H; Eikelboom JW
    J Thromb Haemost; 2013 Feb; 11(2):253-60. PubMed ID: 23216710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
    Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.
    Warkentin TE; Cook RJ; Marder VJ; Greinacher A
    J Thromb Haemost; 2010 Mar; 8(3):504-12. PubMed ID: 20050998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin.
    Griffin JW; Hopkinson WJ; Lassen MR; Thethi I; Litinas E; Fareed J
    Clin Appl Thromb Hemost; 2011; 17(6):567-71. PubMed ID: 22345625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.
    Motokawa S; Torigoshi T; Maeda Y; Maeda K; Jiuchi Y; Yamaguchi T; Someya S; Shindo H; Migita K
    BMC Musculoskelet Disord; 2011 Jan; 12():22. PubMed ID: 21261941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.
    Bito S; Miyata S; Migita K; Nakamura M; Shinohara K; Sato T; Tonai T; Shimizu M; Shibata Y; Kishi K; Kubota C; Nakahara S; Mori T; Ikeda K; Ota S; Minamizaki T; Yamada S; Shiota N; Kamei M; Motokawa S
    Blood; 2016 Feb; 127(8):1036-43. PubMed ID: 26659923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
    Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
    J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.
    Visentin GP; Malik M; Cyganiak KA; Aster RH
    J Lab Clin Med; 1996 Oct; 128(4):376-83. PubMed ID: 8833886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
    Ahmad S; Haas S; Hoppensteadt DA; Lietz H; Reid U; Bender N; Messmore HL; Misselwitz F; Bacher P; Gaikwad BS; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2002 Oct; 108(1):49-55. PubMed ID: 12586132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review.
    Poudel DR; Ghimire S; Dhital R; Forman DA; Warkentin TE
    Platelets; 2017 Sep; 28(6):614-620. PubMed ID: 28856946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid.
    Newman PM; Swanson RL; Chong BH
    Thromb Haemost; 1998 Aug; 80(2):292-7. PubMed ID: 9716155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
    Walenga JM; Prechel M; Jeske WP; Hoppensteadt D; Maddineni J; Iqbal O; Messmore HL; Bakhos M
    Br J Haematol; 2008 Oct; 143(1):92-9. PubMed ID: 18671707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment with fondaparinux in heparin-induced thrombocytopenia and thrombosis].
    Seculini Patiño CE; Pascualini MF; Tabares AH
    Medicina (B Aires); 2015; 75(5):307-10. PubMed ID: 26502466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.
    Ahmad S; Untch B; Haas S; Hoppensteadt DA; Misselwitz F; Messmore HL; Walenga JM; Fareed J
    Mol Cell Biochem; 2004 Mar; 258(1-2):163-70. PubMed ID: 15030181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.
    Lubenow N; Hinz P; Thomaschewski S; Lietz T; Vogler M; Ladwig A; Jünger M; Nauck M; Schellong S; Wander K; Engel G; Ekkernkamp A; Greinacher A
    Blood; 2010 Mar; 115(9):1797-803. PubMed ID: 19965682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux: does it cause HIT? Can it treat HIT?
    Warkentin TE
    Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.